Literature DB >> 30235018

Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?

Gita Thanarajasingam1, Matthew J Maurer2, Thomas M Habermann1, Grzegorz S Nowakowski1, N Nora Bennani1, Carrie A Thompson1, James R Cerhan2, Thomas E Witzig1.   

Abstract

Dietary factors that may reduce the risk of relapse or prolong remission are an area of interest for patients with cancer. There is little data on the role of omega-3 fatty acids (n-3 FA) in patients diagnosed with lymphoma. This pilot biomarker study evaluated the prognostic significance of n-3 FA levels in patients with diffuse large B-cell lymphoma (DLBCL). In this analysis, low n-3 FA may be associated with inferior event free survival at 24 months in this disease. Larger studies are needed to confirm this association and could provide the basis for prospective investigation of whether modifying n-3 levels with diet may improve outcome in lymphoma.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30235018      PMCID： PMC8252913          DOI： 10.1080/01635581.2018.1502328

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN： 0163-5581            Impact factor:   2.900


  10 in total

1.  Nutrient intake and risk of non-Hodgkin's lymphoma.

Authors:  Ellen T Chang; Katarina M Bälter; Anna Torrång; Karin Ekström Smedby; Mads Melbye; Christer Sundström; Bengt Glimelius; Hans-Olov Adami
Journal:  Am J Epidemiol       Date:  2006-09-27       Impact factor: 4.897

2.  Abnormal fatty acid distribution of the serum phospholipids of patients with non-Hodgkin lymphoma.

Authors:  Zorica Cvetković; Vesna Vucić; Bora Cvetković; Milan Petrović; Danijela Ristić-Medić; Jasna Tepsić; Maria Glibetić
Journal:  Ann Hematol       Date:  2010-02-03       Impact factor: 3.673

3.  Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors:  Matthew J Maurer; Hervé Ghesquières; Jean-Philippe Jais; Thomas E Witzig; Corinne Haioun; Carrie A Thompson; Richard Delarue; Ivana N Micallef; Frédéric Peyrade; William R Macon; Thierry Jo Molina; Nicolas Ketterer; Sergei I Syrbu; Olivier Fitoussi; Paul J Kurtin; Cristine Allmer; Emmanuelle Nicolas-Virelizier; Susan L Slager; Thomas M Habermann; Brian K Link; Gilles Salles; Hervé Tilly; James R Cerhan
Journal:  J Clin Oncol       Date:  2014-02-18       Impact factor: 44.544

4.  Trans fatty acid intake is associated with increased risk and n3 fatty acid intake with reduced risk of non-hodgkin lymphoma.

Authors:  Bridget Charbonneau; Helen M O'Connor; Alice H Wang; Mark Liebow; Carrie A Thompson; Zachary S Fredericksen; William R Macon; Susan L Slager; Timothy G Call; Thomas M Habermann; James R Cerhan
Journal:  J Nutr       Date:  2013-03-13       Impact factor: 4.798

Review 5.  The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential.

Authors:  Laura Spencer; Christopher Mann; Matthew Metcalfe; M'Balu Webb; Cristina Pollard; Daniel Spencer; David Berry; William Steward; Ashley Dennison
Journal:  Eur J Cancer       Date:  2009-06-01       Impact factor: 9.162

6.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

7.  Dietary fish intake and risk of leukaemia, multiple myeloma, and non-Hodgkin lymphoma.

Authors:  Lin Fritschi; Gina L Ambrosini; Erich V Kliewer; Kenneth C Johnson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-04       Impact factor: 4.254

8.  Distribution of plasma fatty acids is associated with response to chemotherapy in non-Hodgkin's lymphoma patients.

Authors:  Zorica Cvetković; Vesna Vučić; Bora Cvetković; Ivana Karadžić; Marija Ranić; Marija Glibetić
Journal:  Med Oncol       Date:  2013-10-02       Impact factor: 3.064

9.  Diet and risk of non-Hodgkin lymphoma in older women.

Authors:  B C Chiu; J R Cerhan; A R Folsom; T A Sellers; L H Kushi; R B Wallace; W Zheng; J D Potter
Journal:  JAMA       Date:  1996-05-01       Impact factor: 56.272

10.  Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma.

Authors:  Matthew J Maurer; Jean-Philippe Jais; Hervé Ghesquières; Thomas E Witzig; Fangxin Hong; Corinne Haioun; Carrie A Thompson; Catherine Thieblemont; Ivana N Micallef; Luis F Porrata; Vincent Ribrag; Gregorz S Nowakowski; Olivier Casasnovas; Serge Bologna; Franck Morschhauser; Vicki A Morrison; Bruce A Peterson; William R Macon; Christiane Copie-Bergman; Andrew L Feldman; Sergei I Syrbu; Paul J Kurtin; Randy D Gascoyne; Hailun Li; Cristine Allmer; Brad S Kahl; Stephen M Ansell; Susan L Slager; Brian K Link; Gilles Salles; Thomas M Habermann; Hervé Tilly; James R Cerhan
Journal:  Am J Hematol       Date:  2015-11-26       Impact factor: 10.047
  10 in total
  1 in total

1.  Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis.

Authors:  Liping Fan; Qiuyan Lin; Xiaoling Huang; Danhui Fu; Haobo Huang
Journal:  BMC Cancer       Date:  2021-11-21       Impact factor: 4.430
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.